Evaluating the 6-month formulation of paliperidone palmitate : a twice-yearly injectable treatment for schizophrenia in adults
INTRODUCTION: Paliperidone Palmitate is the only antipsychotic that has been developed in three different intramuscular long-acting injectable (LAI) dosing regimen: monthly (PP1M), quarterly (PP3M), and from 2020 also twice-yearly (PP6M). The latter was approved for the maintenance treatment of adults with schizophrenia and clinically stabilized with PP1M or PP3M.
AREAS COVERED: Data from studies evaluating efficacy in the maintenance treatment of schizophrenia with PP6M are reviewed. Since no post-marketing safety studies are currently available, data from spontaneous reporting system databases, FAERS and Eudravigilance, are analyzed and the reported treatment-emergent adverse events of PP6M are discussed.
EXPERT OPINION: The efficacy of PP6M is comparable to that of PP3M in terms of relapses prevention in patients with schizophrenia previously stabilized on PP3M or PP1M. Also, the maintenance of clinical efficacy in the long term has been demonstrated. Data from pharmacovigilance analyses, as well as from phase 3 studies, show that PP6M is generally well tolerated, consistently with PP3M safety data. PP6M allows a longer dosing interval than any other LAI antipsychotics, potentially reducing nonadherence and disease relapses. In future, an increase in the prescription rates of PP6M is expected and real-world efficacy and tolerability studies will be conducted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Expert review of neurotherapeutics - 24(2024), 4 vom: 31. März, Seite 325-332 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cirnigliaro, Giovanna [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.03.2024 Date Revised 12.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737175.2024.2325655 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369352289 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369352289 | ||
| 003 | DE-627 | ||
| 005 | 20240312234053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737175.2024.2325655 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM369352289 | ||
| 035 | |a (NLM)38445396 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cirnigliaro, Giovanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluating the 6-month formulation of paliperidone palmitate |b a twice-yearly injectable treatment for schizophrenia in adults |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2024 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Paliperidone Palmitate is the only antipsychotic that has been developed in three different intramuscular long-acting injectable (LAI) dosing regimen: monthly (PP1M), quarterly (PP3M), and from 2020 also twice-yearly (PP6M). The latter was approved for the maintenance treatment of adults with schizophrenia and clinically stabilized with PP1M or PP3M | ||
| 520 | |a AREAS COVERED: Data from studies evaluating efficacy in the maintenance treatment of schizophrenia with PP6M are reviewed. Since no post-marketing safety studies are currently available, data from spontaneous reporting system databases, FAERS and Eudravigilance, are analyzed and the reported treatment-emergent adverse events of PP6M are discussed | ||
| 520 | |a EXPERT OPINION: The efficacy of PP6M is comparable to that of PP3M in terms of relapses prevention in patients with schizophrenia previously stabilized on PP3M or PP1M. Also, the maintenance of clinical efficacy in the long term has been demonstrated. Data from pharmacovigilance analyses, as well as from phase 3 studies, show that PP6M is generally well tolerated, consistently with PP3M safety data. PP6M allows a longer dosing interval than any other LAI antipsychotics, potentially reducing nonadherence and disease relapses. In future, an increase in the prescription rates of PP6M is expected and real-world efficacy and tolerability studies will be conducted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adherence | |
| 650 | 4 | |a antipsychotics | |
| 650 | 4 | |a long-acting injectable formulation | |
| 650 | 4 | |a paliperidone palmitate | |
| 650 | 4 | |a psychosis | |
| 650 | 4 | |a schizophrenia | |
| 650 | 4 | |a six-months | |
| 650 | 4 | |a twice yearly | |
| 650 | 7 | |a Paliperidone Palmitate |2 NLM | |
| 650 | 7 | |a R8P8USM8FR |2 NLM | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 700 | 1 | |a Battini, Vera |e verfasserin |4 aut | |
| 700 | 1 | |a Castiglioni, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Renne, Marica |e verfasserin |4 aut | |
| 700 | 1 | |a Mosini, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Cheli, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Carnovale, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Dell'Osso, Bernardo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of neurotherapeutics |d 2001 |g 24(2024), 4 vom: 31. März, Seite 325-332 |w (DE-627)NLM15501806X |x 1744-8360 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:4 |g day:31 |g month:03 |g pages:325-332 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737175.2024.2325655 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 4 |b 31 |c 03 |h 325-332 | ||